Kamada Ltd., a global biopharmaceutical company, expects to achieve 13% revenue growth and 23% adjusted EBITDA growth in 2026, according to recent projections. The company anticipates revenue between $200 million and $205 million and adjusted EBITDA between $50 million and $53 million, representing organic growth from its proprietary specialty plasma therapies and distribution business. Chief Executive Officer Amir London stated the company enters 2026 from a position of significant commercial and financial strength, with expectations for continued organic growth from its diverse commercial product portfolio marketed in over 30 countries. The growth is expected despite reduced royalty payments from Takeda Pharmaceutical Co. Ltd. for GLASSIA, which London cited as evidence of the company's underlying strength.
Growth drivers for 2026 include increased U.S. sales of specialty plasma-derived therapeutics and expanded sales of KAMRAB®, GLASSIA®, HEPAGAM® and VARIZIG® in international markets. The company's Distribution segment is also expected to contribute significantly, particularly through the launch of additional biosimilar products in Israel and expansion into the Middle East and North Africa region. A key component of Kamada's growth strategy involves developing its own plasma collection capabilities through three Texas-based centers. Each of the Houston and San Antonio sites has an annual collection capacity of approximately 50,000 liters of plasma, with estimated annual revenue contribution of $8 million to $10 million at full capacity.
By developing internal plasma collection, Kamada reduces dependency on third-party suppliers and positions itself as a supplier for industry peers through its Kamada Plasma unit, which it describes as one of a limited number of specialty plasma collection firms in the U.S. Beyond organic growth, Kamada is focused on new business development deals and acquisitions that London expects will enrich the company's current portfolio and generate synergies with existing commercial operations. The company anticipates ending 2025 with approximately $75 million in cash and plans to publish its 2025 financial results during the first half of March. Forward-looking statements and additional disclosures are available through the U.S. Securities and Exchange Commission.
